Pharmaceuticals
Yuyu Pharma Unveils New Corporate Logo
SEOUL, South Korea, Sept. 30, 2019 /PRNewswire/ -- Yuyu's corporate logo was
first created in 1941 to honor the company's proud history and highlight Yuyu's
image as a company on the cutting-edge of the industry.
2019-09-30 21:00
1471
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability
SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) released pooled safety data from the Phase Ib (GEMSTONE-101) study of the Company's anti-PD-L1 antibody CS1001 in a poster presentation at the European Society of Medical Oncology 2019 Con...
2019-09-30 18:29
2053
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
2019-09-30 16:30
1012
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
2019-09-30 16:30
2279
Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis
* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...
2019-09-30 15:00
959
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019
NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...
2019-09-30 13:41
997
The 10th China (Taizhou) International Medical Expo successfully ended
NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th
China (Taizhou) International Medical Expo was held in China Medical City
(CMS), according toChina (Taizhou) Medical Expo News Center.
2019-09-30 13:27
1073
Data From Ascensia Diabetes Care Shows High Accuracy of the CONTOUR®PLUS and CONTOUR®PLUS ONE BGMS in Low Blood Glucose Range and Potential Benefits From Using the CONTOUR®PLUS ONE BGMS With the Health2Sync App
HONG KONG, Sept. 30, 2019 /PRNewswire/ -- At the 21st Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Ascensia Diabetes Care has presented data from two studies, one analyzing the accuracy of blood glucose monitoring systems (BGMSs) in the low blood glucose range (LBGR) ...
2019-09-30 09:00
2380
Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019
* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...
2019-09-30 06:00
1511
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...
2019-09-30 05:00
989
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China
NANJING, China and SEOUL, South Korea, Sept. 27, 2019 /PRNewswire/ -- Simcere Pharmaceutical Group and JW Pharmaceutical (KRX:001060, hereinafter called "JWP") announced a collaboration and exclusive license agreement for anti-gout drug candidate URC-102 inChina (including Chinese Hongkong & Maca...
2019-09-27 18:52
4516
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Not intended for US, Canada and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part o...
2019-09-27 14:00
2018
New Clarivate Analytics report shows the cost to bring a drug to market has decreased to under $2B for the first time in over five years
Pharmaceutical R&D industry report provides insights into what's behind decade-high drug approval rates and reveals implications of costs and sustainability LONDON and PHILADELPHIA, Sept. 26, 2019 /PRNewswire/ -- Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted in...
2019-09-26 21:00
6505
Thermo Fisher Scientific Expands Clinical Trials Capabilities and Announces Collaboration with Frontier Biotechnologies Inc.
SUZHOU, China, Sept. 26, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, announced today an expansion of its integrated clinical trials supply and distribution services network, in Suzhou,China, as well as a collaboration with Frontier Biotechnologies Inc. to d...
2019-09-26 14:00
3585
OrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent
HONG KONG, Sept. 26, 2019 /PRNewswire/ -- OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] t...
2019-09-26 01:01
1551
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA's approval of the oral formulation of Akynzeo(R) in China
LUGANO, Switzerland and BEIJING, Sept. 25, 2019 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical Products Administrat...
2019-09-25 12:11
3383
Supply Chain Digitization Creates New Revenue Opportunities in the Vaccine Market
High investment in adult immunization and innovations in DNA vaccines will rejuvenate the vaccines market, finds Frost & Sullivan SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- The need for improved immunogenicity, delivery technologies and reliable supply are driving the shift from the...
2019-09-24 23:28
2071
Global Pharmaceutical Functional and Multifunctional Excipients Industry to Cross the $10 Billion Mark by 2023
SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- Frost & Sullivan's latest analysis,Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023, reveals that the development of innovative drug delivery technologies, a growing generic and biosimilar drug market,...
2019-09-24 22:45
1646
China Biologic Forms Special Committee to Review "Going Private" Proposal
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...
2019-09-24 20:00
12247
PolyU develops a new class of antibiotic candidates for fighting against superbugs
HONG KONG, Sept. 24, 2019 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) has developed a new class of antibiotic drug candidates which has high potential to be developed into a new generation of antibiotics fighting against multi-drug resistant superbugs including methicillin-resist...
2019-09-24 17:46
2090
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 324 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 305 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 276 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
10237
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
8606
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
8129
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
7646
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7167
